Clinical Trial

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Name: The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer — clinical trial record (NCT07134205)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a randomized, open-label, multicenter, phase III clinical study. The aim is to evaluate the efficacy of JMT101 in combination with irinotecan in the third-line and beyond treatment of Metastatic Colorectal Cancer.

Trial Details

NCT Number	NCT07134205
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Metastatic Colorectal Cancer (mCRC)
Enrollment	252 participants
Start Date	2025-10-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-10-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-21